^
Association details:
| Biomarker: | FGFR2 amplification |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Excerpt:
To evaluate the activity of ponatinib in a gastric tumor model in vivo, mice bearing SNU16 xenografts were dosed orally with ponatinib once daily for 21 days (Fig. 4C)….Ponatinib exhibited a dose-dependent effect on tumor growth, with a dose of 3 mg/kg having no effect, 10 mg/kg inhibiting growth by 56% (P < 0.05), and 30 mg/kg inducing tumor regression by 49%.
DOI:
10.1158/1535-7163.MCT-11-0450
